<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783729</url>
  </required_header>
  <id_info>
    <org_study_id>E2006-G000-304</org_study_id>
    <secondary_id>2015-004347-39</secondary_id>
    <nct_id>NCT02783729</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)</brief_title>
  <acronym>SUNRISE 1</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to demonstrate, using polysomnography, that lemborexant 10
      milligrams (mg) and 5 mg is superior to placebo on objective sleep onset as assessed by
      latency to persistent to sleep (LPS) after the last 2 nights of 1 month of treatment in
      participants 55 years and older with insomnia disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicenter, randomized, double-blind, placebo-controlled, active comparator,
      parallel-group study of 2 dose levels of lemborexant for 30 nights in approximately 950
      participants, 55 years or older with insomnia disorder. Participants will be males 65 years
      or older or females 55 years or older. Approximately 60% of the participants will be age 65
      years or older. The study will have 2 phases: The Prerandomization Phase and the
      Randomization Phase. Including both phases, the study will last for a minimum of 65 and a
      maximum of 81 days per participant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">January 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean latency to persistent to sleep (LPS) of lemborexant 10 milligrams (mg) and lemborexant 5 mg compared to placebo</measure>
    <time_frame>Baseline; Days 29 and 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean sleep efficiency (SE) of lemborexant 10 mg and lemborexant 5 mg compared to placebo for United States (US) participants only</measure>
    <time_frame>Baseline; Days 29 and 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean wake after sleep onset (WASO) of lemborexant 10 mg and lemborexant 5 mg compared to placebo for US participants only</measure>
    <time_frame>Baseline; Days 29 and 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in WASO in the second half of the night (WASO2H) of lembrorexant 10 mg and lemborexant 5 mg compared to zolpidem tartrate for US participants only</measure>
    <time_frame>Baseline; Days 29 and 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean SE of lemborexant 10 mg and lemborexant 5 mg compared to placebo for non-US participants only</measure>
    <time_frame>Baseline; Days 29 and 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean WASO of lemborexant 10 mg and lemborexant 5 mg compared to placebo for non-US participants only</measure>
    <time_frame>Baseline; Days 29 and 30</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1006</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Lemborexant 5 milligrams (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one lemborexant 5 mg tablet and one zolpidem-matched placebo tablet each night</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lemborexant 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one lemborexant 10 mg tablet and one zolpidem-matched placebo tablet each night</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zolpidem tartrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive one zolpidem 6.25 mg tablet and one lemborexant-matched placebo tablet each night</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive one zolpidem-matched placebo tablet and one lemborexant-matched placebo tablet each night</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lemborexant</intervention_name>
    <description>Lemborexant 5 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.</description>
    <arm_group_label>Lemborexant 5 milligrams (mg)</arm_group_label>
    <other_name>E2006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lemborexant</intervention_name>
    <description>Lemborexant 10 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.</description>
    <arm_group_label>Lemborexant 10 mg</arm_group_label>
    <other_name>E2006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lemborexant-matched placebo</intervention_name>
    <description>Lemborexant-matched placebo be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.</description>
    <arm_group_label>Zolpidem tartrate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem tartrate</intervention_name>
    <description>Zolpidem tartrate extended release 6.25 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.</description>
    <arm_group_label>Zolpidem tartrate</arm_group_label>
    <other_name>Ambien CR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem-matched placebo</intervention_name>
    <description>Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.</description>
    <arm_group_label>Lemborexant 5 milligrams (mg)</arm_group_label>
    <arm_group_label>Lemborexant 10 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Male age 65 years or older or female age 55 years or older at the time of informed
             consent

          2. Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
             criteria for Insomnia Disorder, as follows:

               -  Complains of dissatisfaction with nighttime sleep, in the form of difficulty
                  staying asleep and/or awakening earlier in the morning than desired despite
                  adequate opportunity for sleep (Note that if the complaint is limited to
                  difficulty initiating sleep, the participant is not eligible)

               -  Frequency of complaint ≥ 3 times per week

               -  Duration of complaint ≥ 3 months

               -  Associated with complaint of daytime impairment

          3. History of subjective wake after sleep onset (sWASO) typically ≥ 60 minutes on at
             least 3 nights per week in the previous 4 weeks

          4. Reports regular time spent in bed, either sleeping or trying to sleep, between 7 and 9
             hours

          5. Reports habitual bedtime, defined as the time the participant attempts to sleep,
             between 21:00 and 24:00 and habitual waketime between 05:00 and 09:00

          6. Insomnia Severity Index (ISI) score ≥ 13

          7. Confirmation of current insomnia symptoms as determined from responses on the Sleep
             Diary before the second screening visit

          8. Confirmation of regular bedtime and waketime as determined from responses on the Sleep
             Diary

          9. Confirmation of sufficient duration of time spent in bed, as determined from responses
             on the Sleep Diary

         10. Objective (polysomnography [PSG]) evidence of insomnia as follows:

             a) Wake after sleep onset (WASO) average ≥ 60 minutes on the 2 consecutive PSGs, with
             neither night &lt; 45 minutes

         11. Willing and able to comply with all aspects of the protocol, including staying in bed
             for at least 7 hours each night

         12. Willing not to start a behavioral or other treatment program for the treatment of
             insomnia during the participant's participation in the study

        Exclusion Criteria

          1. A current diagnosis of sleep-related breathing disorder including obstructive sleep
             apnea (with or without continuous positive airway pressure [CPAP] treatment), periodic
             limb movement disorder, restless legs syndrome, circadian rhythm sleep disorder, or
             narcolepsy, or an exclusionary score on screening instruments to rule out individuals
             with symptoms of certain sleep disorders other than insomnia as follows:

               1. STOPBang score ≥5

               2. International Restless Legs Scale score ≥16

               3. Epworth Sleepiness Scale score &gt;15 (scores of 11 to 15 require excessive daytime
                  sleepiness to be recorded in participant's Medical History)

          2. Reports symptoms potentially related to narcolepsy, that in the clinical opinion of
             the investigator indicates the need for referral for a diagnostic evaluation for the
             presence of narcolepsy

          3. On the Munich Parasomnia Scale (MUPS), endorsed the item that corresponds to a history
             of sleep-eating or reports a history of sleep-related violent behavior, sleep-driving,
             or symptoms of another parasomnia that in the investigator's opinion make the
             participant unsuitable for the study

          4. Apnea-Hypopnea Index &gt; 15 or Periodic Limb Movement with Arousal Index &gt;15 as measured
             on the PSG at the second screening visit

          5. Beck Depression Inventory - II (BDI-II) score &gt;19 at Screening

          6. Beck Anxiety Index (BAI) score &gt;15 at Screening

          7. Habitually naps during the day more than 3 times per week

          8. Is a female of childbearing potential Note: All females will be considered to be of
             childbearing potential unless they are postmenopausal (defined as amenorrheic for at
             least 12 consecutive months, and are postmenopausal without other known or suspected
             cause), or have been sterilized surgically (i.e., bilateral tubal ligation, total
             hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before
             dosing).

          9. Excessive caffeine use that in the opinion of the investigator contributes to the
             participant's insomnia, or habitually consumes caffeine-containing beverages after
             18:00 and is unwilling to forego caffeine after 18:00 for the duration of his/her
             participation in the study.

         10. History of drug or alcohol dependency or abuse within approximately the previous 2
             years

         11. Reports habitually consuming more than 14 drinks containing alcohol per week (females)
             or more than 21 drinks containing alcohol per week (males), or unwilling to limit
             alcohol intake to no more than 2 drinks per day or forego having alcohol within the 3
             hours before bedtime for the duration of his/her participation in the study

         12. Known to be positive for human immunodeficiency virus

         13. Active viral hepatitis (B or C) as demonstrated by positive serology at Screening

         14. A prolonged QT/QTcF interval (QTcF &gt;450 milliseconds [ms]) as demonstrated by a
             repeated electrocardiogram (ECG) at Screening (repeated only if initial ECG indicates
             a QTcF interval &gt;450 ms)

         15. Current evidence of clinically significant disease (e.g., cardiac; respiratory
             including chronic obstructive pulmonary disease, acute and/or severe respiratory
             depression; gastrointestinal; severe hepatic impairment; renal including severe renal
             impairment; neurological including myasthenia gravis; psychiatric disease; or
             malignancy within the past 5 years other than adequately treated basal cell carcinoma)
             or chronic pain that in the opinion of the investigator(s) could affect the
             participant's safety or interfere with the study assessments, including the ability to
             perform tasks on the cognitive performance assessment battery (PAB). Participants for
             whom a sedating drug would be contraindicated for safety reasons because of the
             participant's occupation or activities are also excluded.

         16. Comorbid nocturia resulting in frequent need to get out of bed to use the bathroom
             during the night

         17. Any history of a medical or psychiatric condition that in the opinion of the
             investigator(s) could affect the participant's safety or interfere with the study
             assessment, including the ability to perform the PAB.

         18. Any suicidal ideation with intent with or without a plan, at the time of or within 6
             months before the electronic Columbia-Suicide Severity Rating Scale (eC-SSRS)
             administration during the Prerandomization Phase (i.e., answering &quot;Yes&quot; to questions 4
             or 5 on the Suicidal Ideation section of the eC-SSRS)

         19. Any suicidal behavior in the past 10 years (per the Suicidal Behavior section of the
             eC-SSRS)

         20. Scheduled for surgery during the study

         21. Used any prohibited prescription or over-the-counter concomitant medications within 1
             week or 5 half lives, whichever is longer, before the first dose of study medication
             (Run-in Period).

         22. Used any modality of treatment for insomnia, including cognitive behavioral therapy or
             marijuana within 1 week or 5 half-lives, whichever is longer, before the first dose of
             study medication (Run-in Period)

         23. Failed treatment with suvorexant (Belsomra®) (efficacy and/or safety) following
             treatment with an appropriate dose and of adequate duration in the opinion of the
             investigator

         24. Transmeridian travel across more than 3 time zones in the 2 weeks before Screening, or
             between Screening and Baseline, or plans to travel across more than 3 time zones
             during the study

         25. A positive drug test at Screening, Run-In, or Baseline, or unwilling to refrain from
             use of recreational drugs during the study

         26. Hypersensitivity to lemborexant or zolpidem or to their excipients

         27. Currently enrolled in another clinical trial or used any investigational drug or
             device within 30 days or 5× the half-life, whichever is longer preceding informed
             consent

         28. Previously participated in any clinical trial of lemborexant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jasper Summit Research LLC</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PACT</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Research Partners</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Sleep Medicine Services</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center of Southern California</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Neuropsychiatric Research Center, LLC</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SDS Clinical Trials, Inc.</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute For Clinical Research LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute For Clinical Research</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Monica Clinical Trials</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAB Clinical Research</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Sleep Allergy and Lung Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fleming Island Center For Clinical Research</name>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <zip>32003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS MRA</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Pharmaceutical Services-Miami Research Associates, LLC (QPS MRA)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Centers of America</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroMedical Research Institute</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Group of St Petersburg Inc</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SleepCare Research Institute Inc</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Research Center Inc</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helene A Emsellem MD PC</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Disorders Center of the Mid-Atlantic</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neurophysiology Services</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Clinical Trials</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clayton Sleep Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>8009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLINiLABS, Inc.</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>7724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Unit</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Medicine Centers of Western New York</name>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <zip>14224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Health Associates</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intrepid Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Sleep Medicine Institute</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Sleep Research Center</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleepmed of South Carolina</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Disorders Center of the Mid-Atlantic</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep and Fatigue Institute</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Arts Health Research Group</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somni Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri Hospital Sleep West</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Wake Disorders Clinic</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sleep Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralinstitut für Seelische Gesundheit</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Sleep Research GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Wilhelmshöhe</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somni Bene Institut für Medizinische Forschung und Schlafmedizin Schwerin GmbH</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele S.r.l. - PPDS</name>
      <address>
        <city>Milan</city>
        <state>Lombardia</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST di Pavia - Fondazione Istituto Neurologico Mondino IRCCS</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione PTV Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica del Son Estivill</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Rafael</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones del Sueño</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Araba - Txagorritxu</name>
      <address>
        <city>Vitória</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridge Shire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Surrey</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E2006</keyword>
  <keyword>Lemborexant</keyword>
  <keyword>zolpidem tartrate</keyword>
  <keyword>Ambien CR</keyword>
  <keyword>Insomnia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

